Cardiovascular and microvascular outcomes with iGlarLixi versus iDegLira: A real-world, population-based cohort study. Cowart K, Gonzalez R, Carris NW. Diabetes Obes Metab 2022;24:348-353.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Cowart K, Gonzalez R, Carris NW. Cardiovascular and microvascular outcomes with iGlarLixi versus iDegLira: A real-world, population-based cohort study. Diabetes Obes Metab 2022;24:348-353.
PMID: 34676657